San Diego CA (PRWEB) February 25, 2013
Resource4thePeople announced today that it will provide consumers with updates of a key trial involving allegations that long-term use of the diabetes treatment medication Actos can cause bladder cancer.
The most recent news from the trial in Superior Court of Los Angeles,* where numerous state court cases against Takeda Pharmaceutical Co. have been consolidated, involved evidence about internal concerns among Takeda officials about the safety of Actos.**
“This is an important case that is the first of over 3,000 lawsuits that have been filed against Takeda Pharmaceuticals over allegations that long-term use of the medication puts diabetes patients at increased risk of bladder cancer,” said Resource4thePeople.
“Because of the importance of this trial and the effect that it may have on current cases and on lawsuits that still may be filed we will continue to keep consumers abreast of the developments of the trial while continuing to provide free consultations by our lawyers for those who continue to contact us about their legal rights in regard to Actos use.”
Resource4thePeople said that Actos patients are continuing to inquire whether they are still eligible to file a lawsuit even though the first trial in the litigation is underway.
“The answer is yes, and those who wish to obtain a consultation with an experienced Actos bladder cancer lawyer for an evaluation of what compensation and legal options may be available to them should use the following link,” said Resource4thePeople.
In the Los Angeles trial, Bloomberg News reported that Takeda officials were concerned enough about the link between Actos and bladder cancer that that they conducted a secret survey among physicians to determine whether the doctors would still prescribe the drug if the Actos label warning was changed to reflect increased risk of bladder cancer.**
Bloomberg, which cited the “more than 3,000 lawsuits over Actos,” reported that Takeda Pharmaceuticals “secretly surveyed a dozen doctors in 2003 to see if they would use a diabetes drug with their patients that carried a warning about the potentially fatal ailment.”
The survey, according to the Bloomberg report, found “a bladder cancer warning would destroy the sales of Takeda’s most important drug.”
The Los Angeles trial is one component of the Actos bladder cancer litigation. As this case proceeds other federal court cases that have been consolidated into a federal multi-district litigation are still pending.***
Multi-district litigations are designated by a special federal panel that chooses a single judge to oversee pre-trial evidence-gathering and other legal activities before deciding whether to grant such cases class-action status.
That judge, U.S. District Judge Rebecca Doherty, has scheduled the first bellwether trial in that litigation to be held in November. Bellwether trials are scheduled to allow attorneys for the plaintiffs and defendants to test the strength of their cases.
Resource4thePeople also will be compiling a data bank in which Actos patients and other consumers can reference to obtain information about the possible links between the medication and bladder cancer.
The information will include details from Actos bladder cancer lawsuits, media reports about the litigation and recalls, health advisories and warnings to patients and health care professionals from the Food and Drug Administration.
One of those warnings now included in the Resource4thePeople site was issued by the FDA in 2011 after the agency staff reviewed a Takeda-sponsored study which documented an increased risk of developing bladder cancer with Actos than other diabetes drugs.****
Here is part of the safety announcement:
“The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines. The patient Medication Guide for these medicines will also be revised to include information on the risk of bladder cancer.”
“Consumers and diabetes patients should also be aware of the fact that in this health warning the FDA noted that Actos has been pulled from the pharmacy shelves in France and Germany but has not been recalled in the United States,” said Resource4thePeople.
Another important finding from medical research, according to Resource4thePeople, comes from the findings of a study recently published in Diabetic Medicine, which also links the use of Actos (pioglitazone) to increased risk of bladder cancer.*****
The findings were based on independent research and data from six other studies that included information taken from more than 215,000 diabetes patients.
The authors of the study reached the following conclusion, according to an abstract of the study:
“Pioglitazone use is associated with an increased risk of bladder cancer. Clinicians must consider this increased risk in the context of the baseline risk for bladder cancer of their patients, other adverse features of this medicine (e.g. weight gain, cost) and its potential anti-hyperglycaemic benefits.”
*Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles)
*** In Re: Actos (Pioglitazone) Products Liability Litigation, MDL2299 U.S. District Court, Western District of Louisiana